# Spruce Biosciences Inc. (SPRB)

Source: https://www.quantisnow.com/company/SPRB
Generated: 2026-11-09T12:53:19.396Z

- Ticker: SPRB
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2020
- SEC CIK: 0001683553
- Website: sprucebiosciences.com

## About

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

## Latest SPRB news and filings

- 2026-11-09 12:00 UTC [Spruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences](https://www.quantisnow.com/insight/spruce-biosciences-announces-separation-of-crhx-101-formerly-spr-202-program-into-6780065)
- 2026-11-02 21:05 UTC [Conference Announcement] [Spruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference](https://www.quantisnow.com/insight/spruce-biosciences-to-participate-in-the-guggenheim-3rd-annual-healthcare-6767000)
- 2026-10-15 20:05 UTC [Conference Announcement] [Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference](https://www.quantisnow.com/insight/spruce-biosciences-to-participate-in-the-craig-hallum-biotech-catalyst-conference-6747929)
- 2026-10-08 20:05 UTC [Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting](https://www.quantisnow.com/insight/spruce-biosciences-announces-presentation-of-mps-iiib-natural-history-data-6741735)
- 2026-09-17 12:56 UTC [Analyst Coverage Initiated] [Lake Street initiated coverage on Spruce Biosciences with a new price target](https://www.quantisnow.com/insight/lake-street-initiated-coverage-on-spruce-biosciences-with-a-new-6718618)
- 2026-09-08 20:05 UTC [Conference Announcement] [Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/spruce-biosciences-to-participate-in-the-hc-wainwright-28th-annual-6708194)
- 2026-08-26 12:00 UTC [Spruce Biosciences Announces Launch of MPS3BStudy.com](https://www.quantisnow.com/insight/spruce-biosciences-announces-launch-of-mps3bstudycom-6695006)
- 2026-08-24 12:00 UTC [Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026](https://www.quantisnow.com/insight/spruce-biosciences-announces-positive-pre-bla-meetings-with-fda-and-confirms-6692118)
- 2026-08-14 21:45 UTC [SEC Form SCHEDULE 13G filed by Spruce Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-spruce-biosciences-inc-6683818)
- 2026-08-14 18:05 UTC [SEC Form SCHEDULE 13G filed by Spruce Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-spruce-biosciences-inc-6682673)
- 2026-08-12 13:10 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Spruce Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-spruce-biosciences-inc-6677275)
- 2026-08-12 13:05 UTC [SEC Form 8-K] [Spruce Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/spruce-biosciences-inc-filed-sec-form-8-k-results-of-operations-6677268)
- 2026-08-12 13:00 UTC [Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates](https://www.quantisnow.com/insight/spruce-biosciences-reports-second-quarter-2026-financial-results-and-provides-6677244)
- 2026-08-12 12:00 UTC [Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences](https://www.quantisnow.com/insight/cure-sanfilippo-foundation-and-national-mps-society-make-55-million-6677074)
- 2026-08-04 23:51 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Spruce Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-spruce-biosciences-inc-6663415)
- 2026-08-03 12:00 UTC [Leadership Update] [Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development](https://www.quantisnow.com/insight/spruce-biosciences-appoints-jessica-cohen-pfeffer-md-as-vice-president-6658725)
- 2026-07-29 20:10 UTC [SEC Form 4] [SEC Form 4 filed by Chief Medical Officer Quartel Adrian W](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-medical-officer-quartel-adrian-6653712)
- 2026-07-29 20:09 UTC [SEC Form 3] [SEC Form 3 filed by new insider Quartel Adrian W](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-quartel-adrian-w-6653679)
- 2026-07-27 20:05 UTC [SEC Form SCHEDULE 13G filed by Spruce Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-spruce-biosciences-inc-6649611)
- 2026-07-27 12:05 UTC [SEC Form 8-K] [Spruce Biosciences Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/spruce-biosciences-inc-filed-sec-form-8-k-leadership-update-6649067)
- 2026-07-27 12:00 UTC [Leadership Update] [Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer](https://www.quantisnow.com/insight/spruce-biosciences-appoints-adrian-quartel-md-ffpm-as-chief-medical-6648993)
- 2026-07-13 12:05 UTC [Analyst Coverage Initiated] [B. Riley Securities initiated coverage on Spruce Biosciences with a new price target](https://www.quantisnow.com/insight/b-riley-securities-initiated-coverage-on-spruce-biosciences-with-a-6634876)
- 2026-07-09 20:15 UTC [SEC Form 4] [CHIEF EXECUTIVE OFFICER Szwarcberg Javier B. was granted 266 shares, increasing direct ownership by 1% to 19,270 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-szwarcberg-javier-b-was-granted-266-shares-6633068)
- 2026-07-08 20:01 UTC [Conference Announcement] [Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit](https://www.quantisnow.com/insight/spruce-biosciences-to-participate-in-the-b-riley-securities-2026-6631444)
- 2026-06-29 12:00 UTC [Spruce Biosciences Joins the Russell 3000® Index](https://www.quantisnow.com/insight/spruce-biosciences-joins-the-russell-3000-index-6618288)
- 2026-06-22 12:00 UTC [Leadership Update] [Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs](https://www.quantisnow.com/insight/spruce-biosciences-appoints-agnieszka-jurecka-md-phd-mph-as-vice-6610042)
- 2026-06-16 12:15 UTC [Analyst Coverage Initiated] [Guggenheim initiated coverage on Spruce Biosciences with a new price target](https://www.quantisnow.com/insight/guggenheim-initiated-coverage-on-spruce-biosciences-with-a-new-price-6604022)
- 2026-06-15 12:00 UTC [Leadership Update] [Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller](https://www.quantisnow.com/insight/spruce-biosciences-appoints-eric-jordan-as-vice-president-marketing-and-6601882)
- 2026-06-08 20:05 UTC [Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium](https://www.quantisnow.com/insight/spruce-biosciences-announces-long-term-tralesinidase-alfa-enzyme-replacement-therapy-data-6593261)
- 2026-05-28 20:05 UTC [Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium](https://www.quantisnow.com/insight/spruce-biosciences-announces-data-presentation-at-the-18th-international-mps-6576996)
- 2026-05-27 20:05 UTC [Conference Announcement] [Spruce Biosciences to Participate in Upcoming Conferences in June](https://www.quantisnow.com/insight/spruce-biosciences-to-participate-in-upcoming-conferences-in-june-6574661)
- 2026-05-26 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Spiegelman Daniel K](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-spiegelman-daniel-k-6572593)
- 2026-05-26 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Simpson Camilla V](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-simpson-camilla-v-6572590)
- 2026-05-26 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Barretto-Ko Percival](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-barretto-ko-percival-6572588)
- 2026-05-26 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Executive Chairman Grey Michael G](https://www.quantisnow.com/insight/sec-form-4-filed-by-executive-chairman-grey-michael-g-6572587)
- 2026-05-26 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Walbert Keli](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-walbert-keli-6572552)
- 2026-05-26 20:02 UTC [SEC Form 8-K] [Spruce Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/spruce-biosciences-inc-filed-sec-form-8-k-submission-of-matters-6572000)
- 2026-05-15 20:52 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Spruce Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-spruce-biosciences-inc-6558203)
- 2026-05-15 20:47 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Spruce Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-spruce-biosciences-inc-6558125)
- 2026-05-15 11:24 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Spruce Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-spruce-biosciences-inc-6555624)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SPRB
- Earnings history: https://www.quantisnow.com/earnings/SPRB
- Dividend history: https://www.quantisnow.com/dividends/SPRB
- Insider transactions: https://www.quantisnow.com/insiders/SPRB
- Options chain: https://www.quantisnow.com/options/SPRB
- SEC 8-K filings only: https://www.quantisnow.com/company/SPRB/8-k
- RSS and alerts for SPRB: https://www.quantisnow.com/docs/rss-feeds.md